Wuxi Biologics and Adagene declare Manufacturing and Strategic Development Partnership

Wuxi Biologics and Adagene which is an emerging biotech company discovering and developing innovative antibody therapeutics for its usage globally, declared a collaboration agreement.

Adagene is building a global biotech company with an internal pipeline of antibody therapeutics aiming tough antigens and therapeutic candidates with enhanced biophysical properties. The collaboration with Wuxi Biologics will endorse supply of Adagene’s  products for clinical trials under Investigational New Drug applications in both China and United States.

Dr. Peter Luo, Co-Founder and CEO of Adagene said “The strategic collaboration with WuXi Biologics will enable Adagene to focus on our core competency in the discovery of novel antibody therapeutics and by leveraging the process development and manufacturing capabilities of WuXi Biologics will accelerate Adagene‘snext wave of innovative products into the clinic.”